The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
- PMID: 32169119
- PMCID: PMC7068984
- DOI: 10.1186/s40779-020-00240-0
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
Abstract
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.
Keywords: Clinical characteristics; Coronavirus disease 2019 (COVID-19); Origin; SARS-CoV-2; Therapy; Transmission.
Conflict of interest statement
The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no competing interests.
Figures
Similar articles
-
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6. Infect Dis Poverty. 2020. PMID: 32690096 Free PMC article. Review.
-
Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?Biomolecules. 2020 Sep 11;10(9):1312. doi: 10.3390/biom10091312. Biomolecules. 2020. PMID: 32933047 Free PMC article. Review.
-
Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.OMICS. 2020 Nov;24(11):634-644. doi: 10.1089/omi.2020.0131. Epub 2020 Sep 16. OMICS. 2020. PMID: 32940573 Review.
-
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21. Sci China Life Sci. 2020. PMID: 32009228 Free PMC article. No abstract available.
-
The novel zoonotic COVID-19 pandemic: An expected global health concern.J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671. J Infect Dev Ctries. 2020. PMID: 32235085
Cited by
-
Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2.Signal Transduct Target Ther. 2024 Sep 18;9(1):243. doi: 10.1038/s41392-024-01956-4. Signal Transduct Target Ther. 2024. PMID: 39289355 Free PMC article.
-
Knowledge, attitudes, and practices towards COVID-19 prevention among indigenous population in Malaysia: A cross-sectional study.Sci Rep. 2024 Sep 13;14(1):21428. doi: 10.1038/s41598-024-72519-4. Sci Rep. 2024. PMID: 39271935 Free PMC article.
-
A large scale study of portable sweat test sensor for accurate, non-invasive and rapid COVID-19 screening based on volatile compound marker detection.Sci Rep. 2024 Aug 30;14(1):20148. doi: 10.1038/s41598-024-68250-9. Sci Rep. 2024. PMID: 39209886 Free PMC article.
-
Mucosal immunity in COVID-19: a comprehensive review.Front Immunol. 2024 Aug 14;15:1433452. doi: 10.3389/fimmu.2024.1433452. eCollection 2024. Front Immunol. 2024. PMID: 39206184 Free PMC article. Review.
-
Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples.Viruses. 2024 Jul 25;16(8):1190. doi: 10.3390/v16081190. Viruses. 2024. PMID: 39205164 Free PMC article.
References
-
- WHO . Coronavirus disease (COVID-2019) situation reports. 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous